Articles

Poll

Podcasts

Slideshows

Videos

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

This Q&A interview continues Gooderham's discussion of new upadacitinib treatment data on patients living with severe alopecia areata.

Q&A: Upadacitinib Drives Eyebrow, Eyelash Regrowth with Consistent Safety

This Q&A interview highlights key new data from the UP-AA1 and UP-AA2 trials on upadacitinib for severe alopecia areata.

Q&A: Upadacitinib Meets Primary Endpoint in Severe Alopecia Areata Trials

In this interview, Melinda Gooderham, MD, MSc, touches on eyebrow and eyelash regrowth data and safety findings for upadacitinib in severe alopecia areata.

Upadacitinib Shows Strong Safety Profile in Severe Alopecia Areata

Melinda Gooderham, MD, MSc, discusses new JAMA data on upadacitinib's efficacy for severe alopecia areata in adults and adolescents.

How Much Hair Regrowth Did Upadacitinib Achieve in Severe Alopecia Areata?

In the UP-AA trials, both upadacitinib doses outperformed placebo on SALT score ≤20 at week 24 in adults and adolescents with severe alopecia areata.

UP-AA: Upadacitinib Attains Primary Endpoint in New Alopecia Areata Data

Bempikibart use led to clinically meaningful SALT improvements among those with alopecia areata in the phase 2a SIGNAL-AA study at 36 weeks.

SIGNAL-AA: Bempikibart Effective for Alopecia Areata at 36 Weeks

At Maui Derm NP+PA Summer 2026, Benjamin Ungar, MD, discussed early clues for scarring alopecia, pipeline JAK inhibitors, and setting patient expectations.

Early Signs of Scarring Alopecia, Pipeline Outlook, With Bejamin Ungar, MD

At Maui Derm NP+PA Summer 2026, Benjamin Ungar, MD, detailed how JAK inhibitors and oral minoxidil are reshaping hair loss treatment strategy.

JAK Inhibitors, Oral Minoxidil Reshape Hair Loss Care

This SDPA Summer 2026 talk highlights off-label treatment tips for dermatology clinicians in conditions such as alopecia areata, morphea, and different genital conditions.

What Are Some Tips for Off-Label Medication Use in Dermatology?

Natasha Mesinkovska, MD, PhD, speaks on the potential impact that an additional approved therapy like upadacitinib could have on younger patients with alopecia areata.